Skip to main content

Table 1 Main characteristics of eligible trials

From: Faster recovery and reduced paracetamol use – a meta-analysis of EPs 7630 in children with acute respiratory tract infections

Indication Study, reference Treatment duration, daily dose Maximum daily paracetamol dose allowed% Primary efficacy outcome measure + Number of patients#
EPs 7630 Placebo
Acute tonsillopharyngitis A Timen et al., 2015 [60] 6 days: Day 1–2: 20 drops hourly while awake, Day 3–6: 3 × 20 drops Up to 3 × 500 mg on days 0 to day 4 Response: TSS (7 symptoms) ≤ 4 points at day 4 40 38
B Berezhnoi et al., 2016 [55] 6 days: 3 × 20 drops TSS (5 symptoms): difference baseline – day 4 60 64
C Bereznoy et al., 2003 [56] 6 days: 3 × 20 drops TSS (5 symptoms): difference baseline – day 4 73 70
Acute bronchitis D Kamin et al., 2010a [58] 7 days: Age ≤ 6: 3 × 10 drops
Age 7–10: 3 × 20 drops
Age ≤ 6: 3 × 250 mg Age 7–10: 3 × 500 mg BSS: difference baseline – day 7 25§ 24§
E Kamin et al., 2010b [59] 7 days: 3 × 20 mg (tablets) 3 × 500 mg BSS: difference baseline – day 7 32§& 31§
F Kamin et al., 2012 [57] 7 days: Age ≤ 6: 3 × 10 drops, Age 7–10: 3 × 20 drops Age ≤ 6: 3 × 250 mg Age 7–10: 3 × 500 mg BSS: difference baseline – day 7 35§ 31§
  1. % Only allowed on days with fever ≥38.5 °C
  2. + TSS Tonsillopharyngitis Symptom Score (total score), BSS Bronchitis Symptom Score (total score)
  3. # Primary efficacy analysis data set (full analysis set)
  4. § Only children 6–10 years of age
  5. & Only children randomised to 3 × 20 mg/day